Clinical Trials Logo
  1. Home
  2. Migraine With Aura
  3. NCT04063540

Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura — APAM  

Migraine With Aura Clinical Trial

Official title:
Acid-Sensing Ion Channel and Migraine Disease Proof of Concept Study on the Efficacy of Amiloride in the Prophylaxis of Migraine Aura

Clinical Trial Summary

Recent data suggest involvement of Acid-Sensing Ion Channel channels in the pathophysiology of migraine making these channels a therapeutic target of migraine disease. The implication of Acid-Sensing Ion Channels is discussed through Acid-Sensing Ion Channel-1 which is the most expressed Acid-Sensing Ion Channel channel subtype in the central nervous system. In a mouse model, cortical spreading depression is inhibited by different Acid-Sensing Ion Channel blockers including amiloride which is a non-selective blocker of the Acid-Sensing Ion Channel-1 channel. From a translational perspective, an efficacy of amiloride on a series of migraine patients suffering from severe aura in open conditions. The APAM study is a proof-of-concept study that aims to evaluate the effect of amiloride in the prophylaxis of migraine with aura. This is a randomized crossover study versus placebo conducted in 3 French headache centers.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04063540
Study type Interventional
Source Centre Hospitalier Universitaire de Nice
Contact Emilie PIQUET, Dr
Phone 04 92 03 84 74
Email piquet.e@chu-nice.fr
Status Not yet recruiting
Phase Phase 2
Start date November 2019
Completion date November 2021
View Details
See also
  Status Clinical Trial Phase
Completed NCT02253004 - Induction of Migraine Aura With Cilostazol Phase 0
Recruiting NCT02202486 - Investigation of the Blood-brain and Blood-dura Barrier Durin Migraine Attacks Using MRI N/A
Completed NCT00123201 - Study to Evaluate the Efficacy and Safety of Dronabinol Metered Dose Inhaler (MDI) in Acute Treatment of Migraine Headache Phase 2
Completed NCT04406649 - A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine Phase 3
Completed NCT03874832 - A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects Phase 1
Recruiting NCT05565001 - The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. N/A
Recruiting NCT05416476 - Anisodine Hydrobromide For The Preventive Treatment Of Episodic Migraine Phase 3
Active, not recruiting NCT02906085 - Endothelin-1 as a Potential Trigger of Migraine Aura N/A
Recruiting NCT00893594 - Efficacy of Sumatriptan With Naprosyn in Migraine With Aura N/A
Completed NCT01388699 - Migraine and Endothelial Dysfunction
Completed NCT00534560 - Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache Phase 2
Terminated NCT04936061 - Transnasal Cooling for Migraine N/A
Recruiting NCT05281770 - Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study
Completed NCT03472417 - Partial Rebreathing in the Treatment of Migraine With Aura N/A
Completed NCT00334178 - Evaluation of the Efficacy and Safety of Laxymig® as Prophylactic Treatment in Patients With Migraine Phase 3
Recruiting NCT06051604 - Mi-Helper Transnasal Cooling for Acute Treatment of Migraine N/A
Recruiting NCT06414044 - Italian Real-life obServational Study on the effecTiveness, sAfety and Tolerability of Atogepant in Migraine Patients
Completed NCT03472378 - Can DFN-15 Terminate Migraine With Allodynia? Phase 2
Recruiting NCT05211154 - Evaluation of the Efficacy of Diclofenac Potassium and Rimegepant for the Acute Treatment of Migraine Phase 4
Completed NCT02708797 - Brainstem Grey Matter and Cerebral Autoregulation in Migraine With Aura. N/A